Browse Articles

Evaluating Biomarkers and Treatments for Acute Kidney Injury in a Zebrafish Model

Mathew et al. | Aug 11, 2019

Evaluating Biomarkers and Treatments for Acute Kidney Injury in a Zebrafish Model

Coronary Artery Disease (CAD) is the leading cause of death in the United States, and 81% of Acute Kidney Injury (AKI) patients in the renal fibrosis stage later develop CAD. In this study, Mathew and Joykutty aimed to create a cost-effective strategy to treat AKI and thus prevent CAD using a model of the zebrafish, Danio rerio. They first tested whether AKI is induced in Danio rerio upon exposure to environmental toxins, then evaluated nitrotyrosine as an early biomarker for toxin-induced AKI. Finally, they evaluated 4 treatments of renal fibrosis, the last stage of AKI, and found that the compound SB431542 was the most effective treatment (reduced fibrosis by 99.97%). Their approach to treating AKI patients, and potentially prevent CAD, is economically feasible for translation into the clinic in both developing and developed countries.

Read More...

Simulating single versus cocktail antibiotic effects on the human gut microbiome

Patel et al. | Jul 19, 2026

Simulating single versus cocktail antibiotic effects on the human gut microbiome
Image credit: Volodymyr Hryshchenko

This study, uses SimulATe to model changes in microbial diversity and community structure upon administering a cocktail of antibiotics versus a single antibiotic. The authors hypothesized that antibiotic cocktails, particularly those combining broad-spectrum drugs like tetracyclines and trimethoprims, would cause a more significant reduction in gut microbial diversity compared to single-drug treatments. The findings confirmed a greater loss of microbial diversity with combinatorial treatments compared to single-drug treatments. While individual antibiotics dynamically reshaped the surviving species of the microbiome, antibiotic cocktails frequently cleared all species of the gut microbiome.

Read More...

A novel approach for predicting Alzheimer’s disease using machine learning on DNA methylation in blood

Adami et al. | Sep 20, 2023

A novel approach for predicting Alzheimer’s disease using machine learning on DNA methylation in blood
Image credit: National Cancer Institute

Here, recognizing the difficulty associated with tracking the progression of dementia, the authors used machine learning models to predict between the presence of cognitive normalcy, mild cognitive impairment, and Alzheimer's Disease, based on blood DNA methylation levels, sex, and age. With four machine learning models and two dataset dimensionality reduction methods they achieved an accuracy of 53.33%.

Read More...

Analysis of complement system gene expression and outcome across the subtypes of glioma

Mudda et al. | May 17, 2023

Analysis of complement system gene expression and outcome across the subtypes of glioma
Image credit: National Cancer Institute

Here the authors sought to better understand glioma, cancer that occurs in the glial cells of the brain with gene expression profile analysis. They considered the expression of complement system genes across the transcriptional and IDH-mutational subtypes of low-grade glioma and glioblastoma. Based on their results of their differential gene expression analysis, they found that outcomes vary across different glioma subtypes, with evidence suggesting that categorization of the transcriptional subtypes could help inform treatment by providing an expectation for treatment responses.

Read More...

Impact of gadodiamide (Omniscan) on a beef liver catalase ex vivo model

Hirsch et al. | Mar 10, 2023

Impact of gadodiamide (Omniscan) on a beef liver catalase <em>ex vivo</em> model
Image credit: Marcelo Leal

Here, seeking to better understand the effects of gadolinium-based contrast agents, dyes typically used for MRI scans, the authors evaluated the activity of catalase found in beef liver both with and without gadodiamide when exposed to hydrogen peroxide. They found that gadioamide did not significantly inhibit catalase's activity, attributing this lack of effects to the chelating agent found in gadodiamide.

Read More...